Author(s)

Hala Aziz Shokralla^1*, Mohamed Rahouma²

¹Medical Oncology Department, National Cancer Institute, Cairo, Egypt.
²Surgical Oncology Department, National Cancer Institute, Cairo, Egypt.

Background: Worldwide, lung cancer is the most commonly diagnosed cancer and causes more deaths than any other cancer. In Egypt; it accounts for 7% of male cancer & 3% in females. It is considered to be 3^rd most common cancer in Egyptian males & 6^th most common of both sexes. Materials and Methods: A total of 99 advanced non-small cell lung cancer patients who underwent first line platinum containing chemotherapy in our institute were included in this study. All clinical and pathological data were collected from patient’s files retrospectively between 2012-2014. Results: All 99 cases were diagnosed at late stage IIIB-IV (59 cases were IIIB).The median age was 54 years (range: 30 - 70) with 53% of cases are ≥ 54 years. 71% were males with male: female ratio of 2.4:1. All male patients were chronic smokers. The most frequent symptom was coughing (68%). Most of the patients had primary lung cancer in the right lung (77%). The most common histological subtype was squamous cell carcinoma (35.4%) with 54 cases present with PS-I, the remain was PS-II. All cases received platinum containing chemotherapy. The majority of cases experienced a progressive disease 60.6%. The median progression free survival (PFS) was 6 months & median overall survival (OS) was 18 months. We found that PS, disease stage, pathological subtypes and response to treatment statistically affect both median OS & PFS. Age affects only OS. Conclusions: Our analysis suggests that some of clinico-pathological factors & response to first line platinum containing regimens affect both OS & PFS of advanced NSCLC. This may be beneficial as prognostic markers and further studies were needed to aid in identification and treatment of these patients.

Non-Small Cell, Lung Cancer, Clinico-Pathological, Prognosis, NCI Egypt

Shokralla, H. and Rahouma, M. (2015) Prognostic Clinico-Pathological Features of 99 Cases Advanced Non-Small Cell Lung Cancer—Egyptian National Cancer Institute. Advances in Lung Cancer, 4, 29-36. doi: 10.4236/alc.2015.43005.